The IL-36 receptor may be a new therapeutic target for uncontrolled asthma patients with elevated serum IL-36 levels, as the anti–IL-36R monoclonal antibody can be administered to patients with generalized pustular psoriasis in Japan.39 This evidence concerns the gene IL1RL2 and asthma.